Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cancer immunotherapy in patients with brain metastases

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The exclusion of "real-world" patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a "real-world" setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy : CII
Vol/bind67
Udgave nummer5
Sider (fra-til)703-711
Antal sider9
ISSN0340-7004
DOI
StatusUdgivet - maj 2018

ID: 54806559